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In India, Varki was a physician–scientist at 
the Christian Medical College in Vellore. 
After a few years he moved to the United 
States where he specialized in hematology, 
later became a leading glycobiologist, and 
most recently caught the evolution bug. 
He now codirects the Glycobiology 
Center at the University of California in 
San Diego and the Center for Academic 
Research and Training in Anthropogeny 
(the study of human origins).
Varki’s interest in evolution began a 
decade ago while he was studying sialic 
acids—sugars that coat cell surfaces and 
modulate a variety of physiological and 
pathological process. He discov-
ered that humans can’t synthesize 
one kind of sialic acid (Neu5Gc) 
that other mammals can. How-
ever, in experiments conducted 
partly on himself, Varki found 
that humans incorporate Neu5Gc 
into their bodies when they eat 
red meat (1) and that this incor-
poration has implications for dis-
ease. For example, it may explain why 
diets rich in steaks and burgers might 
predispose some people to toxins (2) or 
lead to chronic inflammation (3). Mean-
while, sialic acid changes that are unique 
to humans help explain why we are 
susceptible to certain diseases, like P. 
falciparum malaria (4). With each new 
finding, Varki drills deeper into the ques-
tion of what makes us human.
How did you transition from glycobiology 
into chimp biology?
After I found a sialic acid diff  erence 
between chimps and humans, I wanted to 
know more about what makes humans 
diff   erent. I went to the Yerkes National 
Primate Research Center to educate my-
self about chimpanzees. I had assumed that 
because they’re genetically so similar to us, 
their diseases were going to be similar to 
ours. But that wasn’t the case! I learned 
that most of the common cancers of hu-
mans had never been reported in the great 
apes. Their heart attacks were completely 
diff   erent than ours. And things like 
bronchial  asth-
ma and rheuma-
toid arthritis, 
which are com-
mon in humans, 
were uncommon 
in apes. Instead 
they tended to 
get strange types 
of renal failure, a 
diff  erent kind of 
cardiac disease, 
and so on. Then 
I thought, well, if we’re genetically so 
similar, but our diseases are so diff  erent, at 
least this should be a tractable problem.
And you approach this problem by 
comparing chimp and human genomes?
Yes, but not just the genomes. There’s a 
complex interaction between our ge-
nomes, our phenomes [the set of possi-
ble phenotypes], and our environment. 
If you don’t take a holistic view, you’ll 
come up short. One of the things I’ve 
been involved in is trying to develop 
networks of people that range from 
linguists to philosophers to biochemists to 
neuroscientists to geneticists. They all 
talk diff   erent languages, but they have 
things to say to each other.
How might a philosopher or linguist 
infl  uence a biologist’s research?
Take the FOXP2 story. A physician 
noticed that there was something un-
usual about a family who supposedly had 
dyslexia—but in fact it wasn’t dyslexia 
because they had problems with articula-
tion and grammar. Plus, it was a familial 
problem. The physician’s fi  nding  was 
picked up by linguists and psychologists 
who showed that it was a global problem 
with aspects of articulation and the speech 
apparatus and not a problem of cognition. 
Eventually geneticists narrowed down 
the disorder to a point mutation in the 
gene  FOXP2. Researchers later cloned 
FOXP2 from human cDNA samples and 
revealed that this gene was uniquely 
changed in humans—two amino acids 
distinguished the human FOXP2 pro-
tein from the one in chimpanzees. And 
recently there was a study in which 
researchers put the human FOXP2 gene 
in a mouse and showed that there were 
slight changes in its vocalizations. None 
of this would have happened if people 
hadn’t been talking across disciplines.
Understanding what makes us human 
is not a problem that will be solved by any 
one specialty. The worst thing you can do 
is to throw away clues that might seem 
irrelevant initially because they may turn 
out to be very important in the end.
TOXIC BURGERS
When did the nonhuman sialic acid 
Neu5Gc fi  rst cross your radar?
I started out as a physician–scientist, 
and one of my patients with a bone 
marrow disease, aplastic anemia, had an 
immune response to the horse serum 
that we were using to treat her. I read 
that this type of response was a reaction 
to sialic acid. At fi  rst I thought it didn’t 
make sense because sialic acids are 
present throughout mammalian cells. A 
decade later, we discovered that humans 
were missing one kind of sialic acid that 
is present in other mammals due to a 
specifi   c genetic event that occurred 
during human evolution.
Since then we’ve found more than 
10 sialic acid–related differences between 
humans and chimpanzees. Sialic acids 
represent a “hotspot” [of mutation] in 
human evolution, and this seems to have 
implications for diseases.
Some say language makes us human, others say it’s art or free will. Ajit Varki 
points out how our diseases set us apart from the apes.
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How so?
Certain pathogens recognize sialic acid 
on the surface of host cells and use it to 
invade. For example, human fl  u binds 
to one acid and the bird fl  u binds to 
another,  so this may explain why the 
bird fl  u has a hard time jumping into 
humans. What is newer is the suggestion 
of molecular mimicry, in which the 
pathogen puts the sialic acid on itself. We 
think that by doing this, the pathogen 
gains protection from complement path-
ways and avoids antibody production.
Does having a unique sialic acid profi  le 
make humans more or less susceptible 
to infection?
It goes in both directions. Because 
humans are missing one kind of sialic 
acid, we are apparently resistant to some 
infections that animals get. One example 
is the malaria that affl   icts the great apes 
in Africa. We found that this malaria 
parasite prefers to bind to a sialic acid 
that’s missing in humans. And the human 
malaria parasite prefers to bind to the 
human sialic acid. So although we had a 
free ride from the original ape malaria 
because we lost one sialic acid, the para-
sites eventually won.
Neu5Gc is present in small amounts in 
some people. I’ve found that it originates 
from our diet—primarily from red meat. 
It turns out that it is present in mammalian 
foods, and as we eat them, the acid gets 
incorporated into our bodies even as we 
make an immune response against it. So 
this is the first example of what I call a 
“xeno-autoantigen.” It’s a xenoantigen 
because it comes from an animal and not 
from humans, but it’s also an autoantigen 
because it gets incorporated into us. Now 
we have a whole program focused on 
trying  to understand the significance of 
anti-Neu5Gc antibodies, the presence of 
this nonhuman molecule in human 
tissues, and how that relates to the fact 
that there are various diseases associated 
with the consumption of red meat. So far 
we have evidence showing that it may 
increase inflammation in carcinomas, and 
we are looking into other diseases.
We also published a paper in 2008 
showing that accumulating Neu5Gc 
from red meat can make you susceptible 
to an E. coli toxin that prefers 
to bind to this nonhuman 
sialic acid (2).
Do you still eat meat?
I haven’t eaten red meat for 
fi  ve or six years since we fi  rst 
discovered this. I mean, I at 
least have to believe my 
own theory, right? Neu5Gc 
is not present in poultry, and 
there are very low amounts 
in fi  sh, so I still eat these foods.
EARTHSHAKING SCIENCE
What else have you found by comparing 
humans with chimps?
Humans have a lot of unusual changes 
in Siglecs [inhibitory receptors on 
white blood cells that dampen the im-
mune response when they bind to sialic 
acid]. We’ve found that the level of ex-
pression of Siglecs in human leukocytes 
is signifi  cantly lower than that in chim-
panzees, especially on T cells. We’ve 
published evidence that human T cells 
tend to be relatively overreactive, and 
we think that this may be because of 
loss of Siglec expression (5). When we 
fi   rst published this article, a science 
writer wrote an article about our work 
saying something about human T cells 
losing their brakes. I wouldn’t say we’ve 
lost the brakes, but maybe we’ve lost 
the power of our brakes. In fact, humans 
have a relative preponderance of T cell–
mediated disorders: rheumatoid arthritis, 
bronchial asthma, HIV with progres-
sion to AIDS, chronic hepatitis. It may 
be that our lymphocyte reactivity is set 
in a diff   erent state than that of our 
evolutionary ancestors.
Another thing about human Siglecs 
is that they turn up in unexpected places. 
Normally they’re on circulating leuko-
cytes. But we’ve found that in humans—
but not in chimps—they show up on 
microglia in the brain. This is due to a 
gene conversion event that upregulates 
Siglec-11 and -16. We don’t know 
exactly what this means, but microglia 
are not only involved in reacting to 
infectious agents but also in human 
inflammatory problems like Alzheimer’s 
and HIV dementia.
Do you encounter resistance when you 
jump from one scientifi  c fi  eld into another?
We run into it a lot. Even though I’m 
a hematologist, I rarely publish in he-
matology journals. I’m into infectious 
diseases, immunology, neuroscience, 
reproductive biology, and so, yes, I en-
counter resistance to 
many of my fi  ndings. But 
the great thing about sci-
ence is that it all comes 
out in the wash in the 
end. You just have to hope 
that it comes about in 
your lifetime. You don’t 
want to be like Alfred 
Wegener, who died on an 
expedition trying to get 
more proof for plate tec-
tonics because everybody 
was castigating him for 
how bad his theory was. Or Copernicus, 
who wrote his fi  nal treatise on the fact 
that the Earth went around the Sun on 
his deathbed.
I’m not saying that my work is 
nearly as important as theirs, but that 
all unexpected findings are met with 
skepticism. Of course, the nice thing 
about working on something totally 
different is that there isn’t much com-
petition, so you can take your time 
and do things right.
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An E. coli toxin (red) preferentially binds Neu5Gc, a sialic 
acid that humans can’t synthesize but can incorporate 
from red meat.
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